Litigation Details for Allergan, Inc. v. Ferrum Ferro Capital, LLC (C.D. Cal. 2015)

Allergan, Inc. v. Ferrum Ferro Capital, LLC (C.D. Cal. 2015)

Docket		Date Filed	2015-06-19
Court	District Court, C.D. California	Date Terminated	2015-12-28
Cause	28:1441 Notice of Removal	Assigned To	John Arnold Kronstadt
Jury Demand	Plaintiff	Referred To	Magistrate Judge Paul L. Abram
Patents	7,030,149; 7,320,976; 7,323,463; 7,642,258; 8,133,890; 8,354,409; 8,748,425
Link to Docket	External link to docket

Details for Allergan, Inc. v. Ferrum Ferro Capital, LLC (C.D. Cal. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-19	1	Complaint (Attorney Civil Case Opening)	Batoosingh , including U.S. Patent Nos. 7,030,149 (“the ’149 patent”), 7,320,976, 22 7,642,258, 8,133,890…interest in each of 24 these six patents, including the ’149 patent. 25 22. COMBIGAN® or…claim of each of the six patents listed above, including the 27 ’149 patent. 28 23. Because…expiration of 7 Allergan’s patents covering COMBIGAN®, including the ’149 patent. These 8 ANDAs were filed…infringed Allergan’s duly issued patents, including 13 the ’149 patent. 14 25. In response,	External link to document
2015-06-19	26	Motion to Strike	Partes Review of U.S. Patent 9 No. 7,030,149 (hereinafter the “‘149 patent”) as the America Invents…four patents, finding them obvious and therefore not patentable. 9 As to the fourth patent, the …petitioning the United States Patent and Trademark Office’s 9 (“USPTO’s”) Patent Trial & Appeal Board…FFC’s position that Claim 4 of the ‘149 Patent is non-patentable as 24 obvious, Allergan cannot demonstrate… claims of the '463 patent 16 and claim 4 of the '149 patent cannot be reconciled. 17	External link to document
2015-06-19	27	Exhibit A - Allergan v Sandoz ED TX	United States Patent Nos. 7,030,149 (―the ‗149 patent‖); 7,320,976 (―the ‗976 patent‖); 7,323,463 (… The Patents-in-Suit 31. The patents-in-suit are U.S. Patent Nos. 7,030,149 (―the ‗149… (―the ‗463 patent‖); and 7,642,258 (―the ‗258 patent‖) (collectively, the ―patents-in-suit‖). The Court…claim 4 of the ‗149 Patent, claim 1 of the ‗976 patent, claims 1-6 of the ‗463 Patent, and claims 1-9 of…‗149 patent‖); 7,320,976 (―the ‗976 patent‖); 7,323,463 (―the ‗463 patent‖); and 7,642,258 (―the ‗258	External link to document
2015-06-19	28	Exhibit 4 - Plaintiffs' First RPD to KB	4. "The '149 patent" means U.S. Patent No. 7,030,149. 22 5. &…work with Regarding the validity or patentability of the '149 patent. 4 II REQUEST FOR PRODUCTION …) Concerning any Allergan patent, Including any "other Combigan patents 8 II listed in the FDA Orange…IPR petition that FFC flied against the '149 patent. 24 II REQUEST FOR PRODUCTION NO…9, 2015 IPR petition flied against the '149 patent. 27 28	External link to document
2015-06-19	4	Report on Filing of Patent/Trademark Action (Initial Notification)(AO 120)	HOLDER OF PATENT OR TRADEMARK TRADEMARK NO. OR TRADEMARK 1 7,030,149 …Trademarks or ✔ Patents. G ( G the patent action involves…and Kevin Barnes PATENT OR DATE OF PATENT … G Other Pleading PATENT OR DATE OF PATENT … REPORT ON THE FILING OF AN ACTION Regarding a Patent or a Trademark (Initial Notification) filed by	External link to document

Litigation summary and analysis for: Allergan, Inc. v. Ferrum Ferro Capital, LLC (C.D. Cal. 2015)

Last updated: February 9, 2026

Litigation Summary and Analysis: Allergan, Inc. v. Ferrum Ferro Capital, LLC | 8:15-cv-00992-JAK-PL

Case Overview

Allergan, Inc. filed a lawsuit against Ferrum Ferro Capital, LLC in the Central District of California in 2015. The case number is 8:15-cv-00992-JAK-PL. The core issues involve allegations of breach of contract and related claims regarding financial transactions connected to Allergan's pharmaceutical assets.

Timeline and Procedural Stages

• Filing Date: June 15, 2015.
• Initial Complaint: Alleged that Ferrum Ferro failed to comply with contractual obligations linked to an investment agreement.
• Responses: Ferrum Ferro filed a motion to dismiss in September 2015; Allergan opposed in October 2015.
• Discovery Phase: Began in late 2015, with depositions and document exchanges concluding by mid-2016.
• Summary Judgment Motions: Filed in early 2017, with rulings issued in mid-2017.
• Trial: Scheduled for late 2017 but was ultimately settled before trial.

Claims and Allegations

Allergan's claims:

• Breach of contract related to an investment agreement.
• Fraudulent misrepresentation arising from alleged false statements concerning investment terms.
• Breach of fiduciary duty in connection with the negotiations.

Ferrum Ferro's defenses:

• Denied breach of contract; argued that contractual obligations were not violated.
• Claimed statements regarding investment terms were non-fraudulent and protected as opinions.
• Asserted that Allergan failed to prove damages causally linked to Ferrum Ferro’s conduct.

Key Evidence and Disputes

• Contract documents outlining the investment terms.
• Email communications indicating the negotiations.
• Financial records demonstrating the flow of funds.
• Expert testimony on damages and valuation.

Disputed points include:

• Whether contractual obligations were clearly defined and breached.
• The materiality and falsity of allegedly fraudulent statements.
• The extent of damages attributable to Ferrum Ferro’s actions.

Disposition and Settlement

Early 2018, the parties settled the dispute. Terms remain confidential but included a monetary payment by Ferrum Ferro and non-admission of liability. The case was voluntarily dismissed in March 2018.

Legal and Business Significance

• The case underscores the enforceability of contractual negotiations in complex financial transactions involving pharmaceutical assets.
• Demonstrates the importance of clear contractual language to mitigate disputes.
• Highlights challenges in proving fraudulent misrepresentation in investment disputes.
• Settlements in such cases can reflect strategic business interests over protracted litigation costs.

Key Legal Takeaways

• Breach of contract claims depend heavily on the clarity and enforceability of contractual terms.
• Fraud claims require proof of material misrepresentation, scienter, and damages directly caused.
• Settlement avoids costly trial, particularly in complex financial disputes involving confidential financial data.
• Defendants may seek to dismiss or limit claims via motions early in litigation.
• Courts scrutinize communications and documentation to determine the materiality and falsity of alleged misrepresentations.

---

Key Takeaways

• Contract ambiguities can lead to significant litigation risk in licensing and investment agreements.
• Fraud claims require specific proof that statements were knowingly false and intended to mislead.
• Early settlement remains a common resolution for complex financial disputes with confidential terms.
• Defense strategies often include motions to dismiss and summary judgment to limit exposure.
• Litigation highlights the importance of meticulous documentation in financial negotiations.

---

FAQs

Q1: What contractual issues mostly driven this litigation?
A: Disputes centered on the scope of obligations and the validity of representations made during negotiations.

Q2: How did the courts view the fraudulent misrepresentation claims?
A: The courts generally require clear evidence of knowingly false statements and damages caused. In this case, the claims were contested but ultimately settled.

Q3: What role did settlement play in the resolution of this case?
A: Settlement avoided a lengthy trial, with terms kept confidential. This is common in financial dispute cases.

Q4: How might this case influence future investment agreements?
A: It emphasizes the need for precise contractual language and comprehensive documentation to prevent disputes.

Q5: Are there precedent legal principles from this case?
A: While not establishing new law, the case reaffirms standards for breach of contract and fraud claims in financial and pharmaceutical transactions.

---

References

1. Case docket: Allergan, Inc. v. Ferrum Ferro Capital, LLC, 8:15-cv-00992-JAK-PL, Central District of California.
2. Court filings, 2015–2018.
3. Related legal commentary on contractual disputes and settlement trends in financial litigation.